Research programme: hepatitis C translation inhibitors - PTC Therapeutics

Drug Profile

Research programme: hepatitis C translation inhibitors - PTC Therapeutics

Alternative Names: Hepatitis C mRNA antagonists - PTC Therapeutics; PTC 725

Latest Information Update: 22 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Jul 2014 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 10 Aug 2009 Development candidate designated from research collaboration between PTC Therapeutics and Schering-Plough for the treatment of Hepatitis C
  • 28 Aug 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top